Natco Pharma Ltd Analyst Rating
based on 11 analysts
45.45%
Buy
18.18%
Hold
36.36%
Sell
Based on 11 analysts offering long term price targets for Natco Pharma Ltd. An average target of ₹1343.09
Source: S&P Global Market Intelligence
Natco Pharma Ltd Share analysis
Natco Pharma Ltd price forecast by 11 analysts
Downside of
High
₹1675
Target
₹1343.09
Low
₹690
Natco Pharma Ltd target price ₹1343.09, a slight downside of -7.37% compared to current price of ₹1449.9. According to 11 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Natco Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:39.23%
Forecast
Actual
Including amortisation and stock based compensations
Natco Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:55.81%
Forecast
Actual
Source: S&P Global Market Intelligence
Natco Pharma Ltd Performance
Day's Low
Day's High
₹1,437.4₹1,464.9552 Week's Low
52 Week's High
₹752.45₹1,639
| Returns % | |
| 1 Month Return | + 1.28 % |
| 3 Month Return | -6.23 % |
| 1 Year Return | + 85.29 % |
| Market Stats | |
| Previous Close | ₹1,441.35 |
| Open | ₹1,445.95 |
| Volume | 6.53L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹25,816.00Cr |
Natco Pharma Ltd Key Statistics
| P/E Ratio | 13.35 |
| PEG Ratio | 0.29 |
| Market Cap | ₹25,816.00 Cr |
| P/B Ratio | 3.05 |
| EPS | 77.56 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 25.38 |
Natco Pharma Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹25,816.00 Cr | 29.97% | 0.54 | ₹1,388 Cr | ₹3,998 Cr | |
| BUY | ₹14,467.33 Cr | -2.21% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹72,870.26 Cr | 35.6% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹98,409.68 Cr | 56.71% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹61,710.00 Cr | 25.5% | 0.53 | NA | NA |
Natco Pharma Ltd Mutual Fund Holdings
About Natco Pharma Ltd
Share Price: ₹1449.90 per share as on 06 Dec, 2024 04:01 PM
Market Capitalisation: ₹25,816.00Cr as of today
Revenue: ₹1,371.10Cr as on September 2024 (Q3 24)
Net Profit: ₹676.50Cr as on September 2024 (Q3 24)
Listing date: 27 Dec, 1995
Chairperson Name: G S Murthy
| Organisation | Natco Pharma Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Natco Pharma Ltd
Natco Pharma Clarifies Impact of Land Sale - 04 Dec, 2024
Natco Pharma announced that the recent sale of land and building does not affect its operational assets or business operations, clarifying that the transaction is not substantial.Bullish Technical Indicators for Natco Pharma - 03 Dec, 2024
Natco Pharma shows a bullish reversal with an Inverse Head and Shoulders pattern and sustained price above the 50-day moving average. The RSI indicates positive momentum, suggesting a buying opportunity around ₹1,400–₹1,410, with targets of ₹1,500 and ₹1,560.Natco Pharma Sells Land, Strengthens Financial Position - 28 Nov, 2024
Natco Pharma sold 14.38 acres of non-operational land in Telangana for Rs 115.57 crore, enhancing its financial position without impacting core operations. Shares rose 1.01% following the announcement.Natco Pharma Sells Land for ₹115.57 Crore - 27 Nov, 2024
Natco Pharma Ltd has completed the sale of 14.38 acres of land in Telangana for ₹115.57 crore. The company confirmed that this transaction will not affect its business operations, as the sold property was not part of its operational assets. Additionally, Natco reported an 83% increase in net profit for the September quarter, indicating strong financial performance.Natco Pharma Declares Interim Dividend for 2024-25 - 26 Nov, 2024
Natco Pharma announced a second interim dividend of Rs 1.50 per share for FY 2024-25, with a record date of November 27, 2024. The stock has shown significant returns over the past two years, despite a slight decline recently.Natco Pharma Submits ANDA for Risdiplam - 21 Nov, 2024
Natco Pharma announced the submission of an ANDA for Risdiplam oral solution, aiming for 180 days of shared marketing exclusivity. The company reported an 83.55% profit surge in Q2 FY25.NATCO Pharma Plans Strategic Acquisitions - 14 Nov, 2024
NATCO Pharma's CEO announced plans for potential acquisitions to enhance growth in the ROW business, leveraging available cash to build their pipeline.Natco Pharma Reports Strong Q2 Earnings Growth - 13 Nov, 2024
Natco Pharma's Q2FY25 results show an 83% increase in net profit to ₹676 crore and revenue growth to ₹1,371 crore. The company also announced a ₹1.50 per share interim dividend.Natco Pharma Reports Strong Q2 Earnings Growth - 12 Nov, 2024
Natco Pharma's Q2FY25 results show a net profit increase of 83% to Rs 676 crore, supported by robust sales and a second interim dividend declared. Revenue rose to Rs 1,371 crore, reflecting strong growth in exports and stable domestic business.
Insights on Natco Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 6 months, NATCOPHARM stock has moved up by 34.0%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 795.6 Cr → 1.43K Cr (in ₹), with an average increase of 17.1% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 212.7 Cr → 677.3 Cr (in ₹), with an average increase of 29.5% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 24.97% to 26.12% in Sep 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, NATCOPHARM has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 17.45% to 17.51% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 142.7% return, outperforming this stock by 66.4%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 49.71% to 49.62% in Sep 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 2.67% to 2.37% in Sep 2024 quarter
Natco Pharma Ltd Financials
Index Inclusions
Natco Pharma Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 49.62% | ||
| Foreign Institutions | 17.51% | 0.32 | |
| Mutual Funds | 2.37% | ||
| Retail Investors | 26.12% | 4.59 | |
| Others | 4.39% |
Natco Pharma Ltd Key Indicators
Natco Pharma Ltd Valuation
Natco Pharma Ltd in the last 5 years
Lowest (11.55x)
January 17, 2024
Today (13.35x)
December 6, 2024
Industry (57.44x)
December 6, 2024
Highest (90.32x)
April 6, 2022
Natco Pharma Ltd Earnings and Dividends
Natco Pharma Ltd Earnings Results
Natco Pharma Ltd’s net profit jumped 83.55% since last year same period to ₹677.30Cr in the Q2 2024-2025. On a quarterly growth basis, Natco Pharma Ltd has generated 1.32% jump in its net profits since last 3-months.
Read More about Earnings ResultsNatco Pharma Ltd Dividends November,2024
In the quarter ending September 2024, Natco Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.48%.
Read More about Dividends
Natco Pharma Ltd Technicals Summary
Bearish
Neutral
Bullish
Natco Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Natco Pharma Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Natco Pharma Ltd shares.
Natco Pharma Ltd (NATCOPHARM) share price today is ₹1449.9
Natco Pharma Ltd is listed on NSE
Natco Pharma Ltd is listed on BSE
- Today’s highest price of Natco Pharma Ltd is ₹1464.95.
- Today’s lowest price of Natco Pharma Ltd is ₹1437.4.
PE Ratio of Natco Pharma Ltd is 13.35
PE ratio = Natco Pharma Ltd Market price per share / Natco Pharma Ltd Earnings per share
Today’s traded volume of Natco Pharma Ltd(NATCOPHARM) is 6.53L.
Today’s market capitalisation of Natco Pharma Ltd(NATCOPHARM) is ₹25816Cr.
| Natco Pharma Ltd(NATCOPHARM | Price |
|---|---|
52 Week High | ₹1639 |
52 Week Low | ₹752.45 |
Natco Pharma Ltd(NATCOPHARM) share price is ₹1449.9. It is down -11.54% from its 52 Week High price of ₹1639
Natco Pharma Ltd(NATCOPHARM) share price is ₹1449.9. It is up 92.69% from its 52 Week Low price of ₹752.45
| Natco Pharma Ltd(NATCOPHARM | Returns |
|---|---|
1 Day Returns | 8.55% |
1 Month Returns | 1.28% |
3 Month Returns | -6.23% |
1 Year Returns | 85.29% |